

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Certolizumab pegol for treating moderate to severe plaque psoriasis [ID1232]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • UCB Pharma (certolizumab pegol) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • British Skin Foundation • Changing Faces • Let's Face it • Muslim Council of Britain • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Society for Cutaneous Allergy • British Society for Rheumatology • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Welsh Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Accord Healthcare (methotrexate) • Actavis UK (acitretin) • Almirall (dimethyl fumarate) • Biogen (etanercept, infliximab) • Celgene (apremilast) • Concordia International (methotrexate) • Eli Lilly (ixekizumab)

Final matrix for the single technology appraisal of certolizumab pegol for treating certolizumab pegol for treating moderate to severe plaque psoriasis [ID1232]

Issue date: June 2018

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social care • NHS England • NHS Oldham CCG • NHS West Essex CCG • Welsh Government 	<ul style="list-style-type: none"> • Genus Pharmaceuticals (acitretin) • Hameln Pharmaceuticals (methotrexate) • Hospira UK (infliximab, methotrexate) • Janssen-Cilag (ustekinumab) • Medac GmbH (methotrexate) • Merck Sharp & Dohme (infliximab) • Mylan (ciclosporin) • Napp Pharmaceuticals (infliximab) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals (ciclosporin, secukinumab) • Orion Pharma UK (methotrexate) • Pfizer (etanercept, methotrexate) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (etanercept, methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • MRC Clinical Trials Unit • National Institute for Health Research • Skin Research Centre • Skin Treatment & Research Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Final matrix for the single technology appraisal of certolizumab pegol for treating certolizumab pegol for treating moderate to severe plaque psoriasis [ID1232]

Issue date: June 2018

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.